Detection of flutamide in pharmaceutical dosage using higher electrospray ionization mass spectrometry (ESI-MS) tandem mass coupled with Soxhlet apparatus  by Khan, Nadeem et al.
Analytical Chemistry Research 3 (2015) 89–97Contents lists available at ScienceDirect
Analytical Chemistry Research
journal homepage: www.elsevier .com/locate /ancrDetection of ﬂutamide in pharmaceutical dosage using higher
electrospray ionization mass spectrometry (ESI-MS) tandem
mass coupled with Soxhlet apparatushttp://dx.doi.org/10.1016/j.ancr.2015.01.001
2214-1812/ 2015 The Authors. Published by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
⇑ Corresponding author at: Department of Chemistry, National Sun Yat Sen
University, Kaohsiung 804, Taiwan. Tel.: +886 7 525 2000/3955; fax: +886 7 525
3908.
E-mail address: hwu@faculty.nsysu.edu.tw (H.-F. Wu).Nadeem Khan a, Hani Nasser Abdelhamid a,b, Ja-Yi Yan a, Fon-Tsai Chung a, Hui-Fen Wu a,c,d,e,f,⇑
aDepartment of Chemistry, National Sun Yat-Sen University, Kaohsiung, 70, Lien-Hai Road, Kaohsiung 80424, Taiwan
bDepartment of Chemistry, Assuit University, Assuit 71515, Egypt
c School of Pharmacy, College of Pharmacy, Kaohsiung Medical University, Kaohsiung 807, Taiwan
d Institute of Medical Science and Technology, National Sun Yat-Sen University, 70, Lien-Hai Road, Kaohsiung 80424, Taiwan
eDoctoral Degree Program in Marine Biotechnology, National Sun Yat-Sen University and Academia Sinica, Kaohsiung 80424, Taiwan
fCenter for Nanoscience and Nanotechnology, National Sun Yat-Sen University, 70, Lien-Hai Road, Kaohsiung 80424, Taiwan
a r t i c l e i n f o a b s t r a c tKeywords:
Electrospray-mass spectrometry
Tandem mass
Flutamide
Eulexin
SoxhletFlutamide (2-methyl-N-[4-nitro-3-(triﬂuoromethyl)phenyl]-propanamide) is a non-steroidal drug that
has a speciﬁc anti-androgenic activity so that it is used in the treatment of prostate cancer. A simple
method for extraction and detection of ﬂutamide from pharmaceutical forms are reported using
Soxhlet apparatus combined electrospray ionization tandem mass spectrometry (ESI()-MSn, n = 14)
in negative ion mode. Spectra show a ﬁngerprint peaks corresponding to ﬂutamide. Propanamide moiety
plays important role in structure elucidation. The diagnostic ions produced a useful ﬁngerprint maps to
identify ﬂutamide in unknown samples. Furthermore, the proposed ions may help in the metabolite stud-
ies of the drug. The method proposed here is easy, cheap and applicable for large quantity.
 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Flutamide (FLA) is an oral non-steroidal anti-androgen drug [1]
that used to treat prostate cancer. IUPAC name of the drug is 2-
methyl-N-[4-nitro-3-(triﬂuoromethyl)phenyl]-propanamide with
nominal mass 276.2 g/mol. FLA competes testosterone, dihy-
drotestosterone (DHT) for binding to androgen receptors in the
prostate gland. The combination of FLA with luteinizing
hormone-releasing hormone agonist or orchiectomy showed sig-
niﬁcant prolongation of survival of prostate cancer patients [2].
FLA may also be used to treat excess androgen levels in women –
especially those with PolyCystic Ovarian Syndrome (PCOS) [3]. 2-
Hydroxy ﬂutamide (antiandrogen) is the active metabolite of FLA
that competitively blocks androgen action accessory sex organs
and on pituitary-increased luteinizing hormone LH and follicle-s-
timulating hormone (FSH) secretion by blocking feedback inhibi-
tion and also decrease the metabolism of C-19 steroids by thecytochrome p-450 system [4]. Plasma testosterone levels increase
in males which partially overcome the direct antiandrogen action
of ﬂutamide. It has been found to be palliative in advanced prostat-
ic carcinoma [5] but it is better used in conjunction with GnRH
against (to suppress LH and testosterone secretion) after castra-
tion. Along with oral contraceptives, it has been tried in female hir-
sutism. Thus, FLA was included in the United States Pharmacopoeia
investigated by chromatographic separation [6], polarography [7],
gas-chromatography (GC) [8], high performance liquid chromatog-
raphy (HPLC) [9–11], photochemistry [12], voltammetric [13] and
electroanalytical methods [14] and others [15–17]. However, few
of the above methods were ever applied for characterization and
elucidation of the FLA structures from its pharmaceutical formula-
tions. Therefore, sensitive detection of the degraded products of
FLA would be very useful for understanding the role in vivo for
the diagnosis of prostatic carcinoma and other related disorders.
Electrospray ionization tandem mass spectrometry (ESI-MS/MS)
is very helpful in drugs studies [18].
Among the different analytical techniques, mass spec-
trometry is superior for drug/organic molecules detections
[19–25]. It is simple, easy, sensitive, and give information about
the structure. Furthermore, it is convenient to conjugate with
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Scheme 1. (A) Systematic representation of the Soxhlet extraction and ESI-MSn detection, and (B) Proposed fragmentation pattern of the [M-H] ion of extracted ﬂutamide.
90 N. Khan et al. / Analytical Chemistry Research 3 (2015) 89–97separation techniques such as gas chromatography (GC), HPLC
or others separation techniques. However, it is destructive.
Moreover, it is trivial limitation for soft ionization such as
matrix assisted laser desorption/ionization mass spectrometry
(MALDI-MS) and ESI-MS [26–33]. It is also not require any fur-
ther chemicals [34–36].
The main targets of the present report are separation and eluci-
date the fragmentation of ﬂutamide from its pharmaceuticalformulation using ESI-MSn. A map of the drug fragmentation is elu-
cidated for simple and accurate detection of FLA. Soxhlet apparatus
was used to extract the drug from the pharmaceutical formulation.
The efﬁciency of the extraction was evaluated using HPLC and
authentic sample. The extracted drug was detected using ESI-
MSn. The drug fragmentation was undergoes tandem mass in order
to elucidate the drug structure. The data show unexpected peaks
can be used as ﬁngerprint of the drug.
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Fig. 1. (A) ESI()-MS spectrum of extracted Flutamide, (B) ESI()-MS spectrum of pure Flutamide.
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2.1. Reagents and samples
The pure ﬂutamide (standard) was purchased from Echo
Chemical Company (Kaohsiung, Taiwan). A commercial dosage
(Eulexin) form of ﬂutamide was purchased from the local pharma-
ceutical market (Kaohsiung, Taiwan). Methanol was purchased
from Mallinckrodt (Phillipsburg, NJ, USA). The deionized water
was puriﬁed on a Milli-Q reagent water system (Millipore,
Milford, MA, USA). All other reagents and solvents used were of
analytical grade. ACD/ChemSketch vs12 program was used to draw
and calculate the theoretical mass of the chemical structures of the
m/z peaks.2.2. Extraction of ﬂutamide
Ten commercial tablets of FLA were powdered, mixed thor-
oughly and dissolved in methanol, which is then extracted by using
soxhlet extractor [37]. The extraction solvent (methanol) wascontinuously cycled through the sample by distilling the solvent
to condense centered over the thimble. The condensed solvent per-
meated through the matrix and the thimble and was siphoned
back into the pot, where it was recycled. The extracted material
was concentrated in the pot by evaporating the solvent using
low temperature and reduced pressure for rapid solvent removal.
Recrystallization of an extracted drug was performed by using
the same solvent.3. Instrumentations
3.1. Chromatographic conditions
The HPLC experiments were performed onWaters 2795 module
chromatographic system using diode array as the UV detector. The
symmetry column C18, 4.6  75 mm, 3.5 lm (Waters Corporation,
Milford, USA) was used for analysis. The mobile phase used was
acetonitrile (A) with buffer (B) containing 0.05% ammonium acet-
ate in water with gradient system – Time % of B: 0/70, 1/70, 2/
20, 10/20, 10.5/70, 13/70.
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All experiments were performed in an ion trap tandem mass
spectrometer (Thermo Finnigan LCQ-Advantage, San Jose, CA,
USA) equipped with an ESI source. All ESI()-MS spectra were
acquired in the negative ion mode. Samples were introduced
through a 0.5 mm i.d. stainless steel heated capillary (12 cm
length; 15–20 V) at a ﬂow rate of 5 L/min. The spray voltage of
5 kV was applied to the tip of capillary, which is situated within
the ionization source of the mass spectrometer. A potential of
15–25 V was applied to a focusing stainless steel tube lens located
at the end of the capillary. Ions from the source are guided into an
ion trap mass analyzer, which is operated with automated gain
control (AGC) on, for all experiments. In this mode, the instrument
can automatically select the best trapping parameters to keep the
number of the ions present in the trap at a constant value in order
to avoid space charge effects. The ion trap is operated in the mass-
selective instability mode. All MSn experiments were performed by
tuning the percentage of collision activated dissociation (CAD)
voltages in order to optimize the dissociation energy for the pre-
cursor ions. An aliquot of 10 ppm of extracted solution of FLA in
methanol was injected into the mass spectrometer. The scan range
of mass spectra is fromm/z 50 to 500. All experiments were repeat-
ed at least three times to ensure the reproducibility.Table 1
Observed product ions in ESI()-MSn mass spectra of extracted ﬂutamide.
ESI()-MSn Precursor ion Fragment ion m/z Value
ESI()-MS1 275.13 [M-H] 275.13
[M+35Cl] 310.75
[M+37Cl] 312.76
ESI()-MS2 275.13 [M-C4H6O-H2] 202.03
[M-CH(CH3)2-H] 231.75
[M-C4H6O-H] 205.03
310.07 [M-H-HCl] 275.02
364.06 [M275-H+C4H6O+H2O] 275.01
ESI()-MS3 275.1 [M-C4H6O-H2-H] 201.95
[M-CH(CH3)2-H] 231.74
310.7 [M-H-HCl] 275.00
[M-HCl-C4H6O-H2] 202.00
[M-HCl-C4H5O-H] 205.00
[M-HCl-CH(CH3)2-H] 231.75
364.6 [M275-H+C4H6O+H2O] 274.99
[M-HCl-C4H6O-H2-H] 201.98
ESI()-MS4 310.7 [M-HCl-CH(CH3)2-H] 231.77
[M-HCl-C4H6O-H2-H] 201.98
364.6 [M-CH(CH3)2-H] 231.72
[M-C3H6O3-HCl-C4H6O-H2-H] 201.944. Results and discussion
Separation or extraction of the drug from their pharmaceutical
formulation is highly demanded for detection [38]. Systematic rep-
resentation of the drug extraction is shown in Scheme 1A. Because
of the limit solubility of ﬂutamide, Soxhlet extraction is used.
Typically, Soxhlet is also make the impurity is insoluble in that sol-
vent. The extracted drug is elucidated by electrospray ionization
mass spectrometry (ESI-MS). The efﬁciency of the Soxhlet separa-
tion is evaluated HPLC. In order to elucidate the total peaks of
the drug, tandam mass was investigated.
4.1. HPLC separation and detection on the commercial dosage of FLA
The purity of the extracted drug was found to be 99.47% deter-
mined by HPLC experiments Fig. S1 (Supporting information). The
retention time of the FLA separated from the commercial dosage by
HPLC with the UV detector (kmax = 254 nm) was observed at
4.70 min (Fig. S1). The absorption refers to the B-band of the ben-
zene ring. The high purity of the extracted ﬂutamide indicates the
high efﬁciency of Soxhlet.
4.2. ESI()-MS detection of FLA
The ESI()-MS results of the extracted (tablets) and pure FLA
(standards) are shown in Fig. 1A and Fig. 1B, respectively.
Compared with the standard FLA, the ESI()-MS results of the
FLA tablets are in agreement with those of the standard FLA in
regards to the formation ions. The assignments of ESI()-MS ions
are listed in Table 1. Nominal mass of ﬂutamide is 276.2 g/mol.
Both pure and extracted ﬂutamide show the same peaks. The
ESI-MS ions observed atm/z 275.1, 276.1, 310.7, 312.7 are assigned
as [MH], [M(13C)H], [M+35Cl], [M+37Cl] respectively. The
ions at m/z 310.7 and 312.7 are chlorine isotopic patterns of the
adduct ion of the drug with ubiquitous ion (Cl). The intensity ratio
between peaks at m/z 310.7 and 312.7 is 3:1 which is in agree-
ment with the same ratio of Cl35:Cl37 = 3:1 (see Eq. (1)). The two
peaks can be used as ﬁngerprints for identiﬁcation of FLA in nega-
tive mode. The ESI()-MS shows a product ion at m/z 364.61 in
both pure and extracted ﬂutamide spectrum Fig. 1A and B. Thestructure of this peak is unexpected, so we master MS2, and MS3
to elucidate the structure.Cl35
Cl37
¼ Intensity of peak 310:75
Intensity of peak 312:75
¼ 9;000;000
2;950;000
¼ 3:05
1
ð1Þ4.3. High order tandem ESI-MS results of FLA
The major metabolite of FLA in plasma is 2-hydroxyﬂutamide
(OH-ﬂutamide), whose formation from ﬂutamide is catalyzed by
CYP1A2 [39,40]. Whereas the main metabolite in urine is 2-
amino-5-nitro-4-(triﬂuoromethyl) phenol (FLU-3) [41]. A new
metabolite, N-[4-nitro-3-(triﬂuoromethyl) phenyl]hydroxylamine
(FLU-1-N-OH), was detected as a product of the reaction of
FLU-1 with human liver microsomes and identiﬁed by compar-
ison with the synthetic standard. The formation of FLU-1-N-OH
was markedly inhibited by the addition of miconazole, an inhibi-
tor of CYP3A4, and was mediated by recombinant CYP3A4 [42].
Microbial models retrospectively of mammalian metabolites of
ﬂutamide investigated which may help to identify factors
responsible for toxicity [43]. The MS/MS results on the main
ESI-MS product ions of m/z 275.1, 310.0 and 364.0 are shown
in Table 1 and Figs. 2 and 3. By performing MS/MS of m/z
275.1 (the precursor ion), the fragment ions were observed at
m/z 202.0, 205.0, 203.0 and 231.7 which are corresponding to
[M-C4H6O-H2-H], [M-C4H6O-H], [M-C4H6O-H2-H] and [M-
CH(CH3)2-H], respectively (Fig. 2A). In this rearrangement, a
stable hexagonal ring formed that provides high stability of the
anion according to Baeyer Strain theory and the development
of Strain Theory [44]. The m/z 205.0 ([M-C4H6O-H]) ion under-
goes hydrogen extrusion and to form azepine ring (seven nitro-
gen ring) that demonstrate high stability. Simply, this peak is
deprotonated aniline derivative. Formation of 1,3-benzoxazole
aromatic system results in the m/z 231.7 have high intensity
due to the aromatic system stabilization energy (Fig. 2A). MS3
and MS4 of precursor m/z 310.7 are reported in Fig. 3B and C.
This precursor fragmentation was described in Scheme 1B.
Peak at m/z 364.6 is unexpected, so we master MS2, MS3, and
MS4 to propose a reasonable structure of this peak. If we recheck
Fig. 1A, B again (which observed in both extracted and pure ﬂu-
tamide, respectively), we observe presence of the peak at m/z
Fig. 2. (A). ESI()-MS2 spectrum of ion at m/z 275.1, (B) ESI()-MS3 spectrum of ion at m/z 275.1.
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inactive excipients of the drug. MS2 spectra Fig. 4A of ion at m/z
364.6, shows only the peak at m/z 275.1. While, MS3 spectra of
ion at m/z 364.6, shows peaks at m/z 231.76, 204.99 and 201.98
that be clear explained in Scheme 1B.This peak can assigned as
adduct ion between the drug itself and propanal moiety.
Propanal moiety (C4H6O) that come from the drug itself. This group
can easily exist due to fragmentation to amide and anilinederivative. The peak at m/z 364.6 can recognized as [M275–
H+C4H6O+H2O]. The peaks assignment was tabulated in Table 1.
Comparison among the different technique that reported for
ﬂutamide detection is tabulated in Table 2. ESI-MSn is sensitive,
simple, rapid and gives information about the drug structure.
However, visible spectrophotometric is simple, rapid, precise, sen-
sitive, and accurate for the estimation of ﬂutamide in both pure
and pharmaceutical preparations [45]. It cannot give information
Fig. 3. (A) ESI()-MS2 spectrum of ion at m/z 310.7, (B) ESI()-MS3 spectrum of ion at m/z 310.7, (C) ESI()-MS4 spectrum of ion at m/z 310.7.
94 N. Khan et al. / Analytical Chemistry Research 3 (2015) 89–97about the drug structure. Recently (2014), Aslam et.al reported a
simple and sensitive spectrophotometric method for the determi-
nation of ﬂutamide (FLD) [46]. The method is based on its com-
plexation and oxidation of FLA by Fe3+ and 1,10-phenanthroline.
However, it required extra chemical i.e., Fe3+ and 1,10-phenanthro-
line. Based on the reduction of the nitro organic moiety of the drug
molecule using cathodic stripping voltammetric at the hanging
mercury drop electrode was optimized for determination ofﬂutamide in bulk, tablets, and human [47]. However, mercury is
highly toxic and hydrogen overpotential is limit the concentration
detection.
5. Conclusion
We successfully introduce a rapid and simple method to detect
the ﬂutamide from its formulation. Furthermore, this study has
Fig. 4. (A) ESI()-MS2 spectrum of ion at m/z 364.6, (B) ESI()-MS3 spectrum of ion at m/z 364.6, (C) ESI()-MS4 spectrum of ion at m/z 364.6.
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trometry (ESI()-MSn, n = 1–4) can be employed in negative ion
mode. The Soxhlet apparatus combined ESI-MSn can elucidate the
structures and study the fragmentation patterns of commercial
FLA drugs. Subsequent MSn experiment reveals the liability of the
propanamide group attached to the phenyl ring and inertness of
triﬂuoromethyl moiety. Proponamide group plays also role todetect ﬂutamide from any pharmaceutical formulation. This can
be proved by peak atm/z 364.6 as a ﬁngerprint. The diagnostic ions
can be used as ﬁngerprint maps to identify FLA in unknown sam-
ples. The current approach is an effective technique to analyze
the drugs in commercial dosage forms. Furthermore, ESI()/MS
map allows the analysis of the drug in environmental or biological
samples. The assigned peaks may help in metabolite studies.
Table 2
Comparison among the different technique that reported for ﬂutamide detection.
Technique LOD Linear range Sample Mechanism Ref.
Spectrophotometric method 0.332 and 0.726 lg mL1 0.5–10 lg mL1 Standard and urine Complexation and oxidation of FLA by Fe3+
and 1,10-phenanthroline
45
Visible spectrophotometric 0.0395, 0.0345,
0.0854 lg mL1
0.5–12, 0.5–10, and
0.3–10 lg mL1
Pure and
pharmaceutical
preparations
Absorption 46
Adsorptive cathodic
stripping voltammetric
1.9  107, 8.7  108, and
9.7  109 mol L1
Bulk, tablets, and human
serum
Reduction of the nitro organic moiety 47
ESI-MSn 0.001 lg mL1 Pure and
pharmaceutical
formulation
Ionization Here
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